期刊文献+

清化消瘀方对糖尿病合并动脉粥样硬化患者糖基化过程影响的研究 被引量:2

Study of the effects of Qinghuaxiaoyu Decoction on advanced glycation end products of diabetic merging arteriosclerosis
下载PDF
导出
摘要 目的:观察清化消瘀方对糖尿病合并粥样动脉硬化患者糖基化过程的影响。方法:60例糖尿病合并粥样动脉硬化患者随机分为治疗组30例(清化消瘀方加西药常规治疗),对照组30例(西药常规治疗),疗程4周,治疗前后测定血清糖基化终产物(AGEs)、hs-CRP、IL-6、TNF-α值,并取正常组20例予以对照。结果:治疗前治疗组血清AGEs(64.46±12.10)U/ml、hs-CRP(5.47±5.96)mg/L、IL-6(2.53±0.57)mg/L、TNF-α(2.31±0.67)μg/L,与对照组水平相当,与正常对照组比较均明显升高(P<0.05),而治疗后治疗组血清AGEs(37.3±5.75)U/ml、hs-CRP(1.24±0.57)mg/L、IL-6(2.19±0.63)mg/L、TNF-α(1.96±0.42)μg/L均明显降低(P<0.05),与正常对照组比较差异无统计学意义(P>0.05)。结论:糖尿病合并动脉粥样硬化患者由于糖基化过程导致糖基化终产物含量增高,清化消瘀方能阻断这一进程,降低其含量,从而抑制糖尿病动脉粥样硬化的形成和发展。 Objective: To observe the effect of Qinghuaxiaoyu Decoction on advanced glycation end products of diabetic merging arteriosclerosis.Methods: 60 patients with diabetic merging arteriosclerosis were randomoly divided into 2 groups,control group(n=30) was treated with Metformin Hydrochloride Tablets;treatment group(n=30) was treated with Metformin Hydrochioride Tablets and Qinghuaxiaoyu Decoction.Course of treatment was 4 weeks.AGEs,hs-CRP,IL-6,TNF-α were determined before and after treatment.Results: AGEs,hs-CRP,IL-6,TNF-α were increased obviously in both groups before treatment.AGEs,hs-CRP,IL-6,TNF-α were decreased obviously in treatment group after treatment.Conclusion: Qinghuaxiaoyu Decoction has steady and tried effect on diabetic merging arteriosclerosis,the possible mechanism is decreasing advanced glycation end products.
出处 《中国医药导报》 CAS 2011年第13期64-66,共3页 China Medical Herald
基金 2009年深圳市科技计划项目(项目名称:清化消瘀方对糖基化及其介导炎症反应影响的研究 项目编号:200903215)
关键词 清化消瘀方 糖尿病 动脉粥样硬化 糖基化终产物 炎症介质 Qinghuaxiaoyu Decoction Diabetes Arteriosclerosis Advanced glycation end products Mediators of inflammation
  • 相关文献

参考文献4

二级参考文献26

  • 1BASTA G, SCHMIDT A M, DE CATERINA R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes [J].Cardiovasc Res, 2004, 63(4): 582 - 592.
  • 2LOPES-VIRELLA M F, VIRELLA G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes [J] . Front Biosci, 2003, 8:S750 - 768.
  • 3OHGAMI N, MIYAZAKI A, SAKAI M, et al. Advanced glycation end products (AGE)inhibit scavenger roceptor class B type Ⅰ-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism [J]. J Atheroscler Thromb,2003, 10(1): 1 -6.
  • 4AHMED N. Advanced glycation endproducts-role in pathology of diabetic complications[J] . Diabetes Res Clin Pract, 2005, 67(1):3-21.
  • 5SCHMIDT A M, YAN S D, WAUTIER J L,et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis [J] . Circ Res, 1999, 84(5): 489 - 497.
  • 6WAUTIER J L, WAUTIER M P. Blood cells and vascular cell interactions in diabetes[J]. Clin Hemorheol Microcirc, 2001, 25(2):49 -53.
  • 7ASANO G, TAKASHI E, ISHIWATA T, et al. Pathogenesis and protection of ischemia and reperfusion injury in myocardium [J]. J Nippon Med Sch, 2003, 70 (5) : 384 - 392.
  • 8BEAUCHAMP M C, MICHAUD S E, LI L,et al. Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression[J] . J Lipid Res, 2004, 45(9): 1749-1757.
  • 9CIPOLLONE F, IEZZI A, FAZIA M, et al. The receptor RACE as a pregression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control [J] .Circulation, 2003, 108(9):1070 - 1077.
  • 10BURKE A P, KOLODGIE F D, ZIESKE A,et al. Morphologic findings of coronary atberosclerotic plaques in diabetics: a postmortem study [J] . Arterloscler Thromb Vasc Biol, 2004, 24(7): 1266-1271.

共引文献21

同被引文献27

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部